LXEO Strangle Strategy
LXEO (Lexeo Therapeutics, Inc. Common Stock), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
LXEO (Lexeo Therapeutics, Inc. Common Stock) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $373.0M, a beta of 1.39 versus the broader market, a 52-week range of 3.6-10.99, average daily share volume of 880K, a public-listing history dating back to 2023, approximately 75 full-time employees. These structural characteristics shape how LXEO stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.39 indicates LXEO has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a strangle on LXEO?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current LXEO snapshot
As of June 29, 2026, spot at $4.82, ATM IV 7.00%, IV rank 1.24%, expected move 2.01%. The strangle on LXEO below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 18-day expiry.
Why this strangle structure on LXEO specifically: LXEO IV at 7.00% is on the cheap side of its 1-year range, which favors premium-buying structures like a LXEO strangle, with a market-implied 1-standard-deviation move of approximately 2.01% (roughly $0.10 on the underlying). The 18-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated LXEO expiries trade a higher absolute premium for lower per-day decay. Position sizing on LXEO should anchor to the underlying notional of $4.82 per share and to the trader's directional view on LXEO stock.
LXEO strangle setup
The LXEO strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With LXEO near $4.82, the first option leg uses a $5.06 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed LXEO chain at a 18-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 LXEO shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $5.06 | N/A |
| Buy 1 | Put | $4.58 | N/A |
LXEO strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
LXEO strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on LXEO. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on LXEO
Strangles on LXEO are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the LXEO chain.
LXEO thesis for this strangle
The market-implied 1-standard-deviation range for LXEO extends from approximately $4.72 on the downside to $4.92 on the upside. A LXEO long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current LXEO IV rank near 1.24% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on LXEO at 7.00%. As a Healthcare name, LXEO options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to LXEO-specific events.
LXEO strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. LXEO positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move LXEO alongside the broader basket even when LXEO-specific fundamentals are unchanged. Always rebuild the position from current LXEO chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on LXEO?
- A strangle on LXEO is the strangle strategy applied to LXEO (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With LXEO stock trading near $4.82, the strikes shown on this page are snapped to the nearest listed LXEO chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are LXEO strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the LXEO strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 7.00%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a LXEO strangle?
- The breakeven for the LXEO strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current LXEO market-implied 1-standard-deviation expected move is approximately 2.01%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on LXEO?
- Strangles on LXEO are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the LXEO chain.
- How does current LXEO implied volatility affect this strangle?
- LXEO ATM IV is at 7.00% with IV rank near 1.24%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.